The company is a dormant entity that historically traded in footwear components, synthetic shoe soles, and chemicals, but currently generates no operational revenue and focuses on recovering old dues.
The company has no competitive advantage, as evidenced by zero revenue from operations for multiple consecutive years and a net margin of -142.1%. There is no evidence of brand power, scale, or proprietary technology that would prevent competitors from entering its historical markets.
Capital allocation is restricted to survival; the company relies on unsecured loans from directors to pay for listing fees, audit fees, and minimal administrative costs. There is no reinvestment in growth or productive assets, and net worth is entirely eroded.
The company finally succumbed to its 'going concern' status as the lack of revenue for over eight years made it impossible to settle long-standing customs duty defaults. The reliance on unsecured director loans proved unsustainable when the board could no longer justify funding listing fees for a shell entity with no operations. The stock price eventually collapsed toward its negligible intrinsic value as the market realized that no turnaround was coming and the accumulated losses had permanently hollowed out the equity.
RichFakir rates Standard Shoe Sole & Mould India Ltd's business quality as poor — 0/100 on our quality score (profitability, growth, balance-sheet strength and capital allocation). We assess its competitive moat as none.
On our model, Standard Shoe Sole & Mould India Ltd is trading far above our estimate of fair value (expensive on our lens); we rate its price expensive. This is an educational estimate from public filings, not a recommendation.
RichFakir's educational verdict on Standard Shoe Sole & Mould India Ltd is: Avoid. We are steering clear of this one — the red flags below outweigh anything the price or numbers offer.
RichFakir's educational estimate of Standard Shoe Sole & Mould India Ltd's fair value is about ₹1 per share, derived from public filings. It's our estimate for research — not a price target or a recommendation to buy or sell.
View the full live analysis →